Showing results (101-110 of 108) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Oncotarget|March 24, 2018
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumorsBruce W Konicek, Andrew R Capen, Kelly M Credille, et al.Journal of Medicinal Chemistry|August 3, 2021
Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor InteractionDavid C McKinney, Brian J McMillan, Matthew J Ranaghan, et al.Bioorganic & Medicinal Chemistry Letters|January 24, 2007
Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active siteScott M Sheehan, Hans-Juergen Mest, Brian M Watson, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2011
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitorPatrick C May, Robert A Dean, Stephen L Lowe, et al.Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.Bioorganic & Medicinal Chemistry|December 2, 2019
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraintsLeonard L Winneroski, Jon A Erickson, Steven J Green, et al.Journal of Medicinal Chemistry|June 3, 2021
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorDavid L McKinzie, Leonard L Winneroski, Steven J Green, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 23, 2015
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humansPatrick C May, Brian A Willis, Stephen L Lowe, et al.Pageof 11